Last Price
68.34
Today's Change
+0.777 (1.14%)
Day's Change
66.64 - 68.35
Trading Volume
1,480
Market Cap
7 Billion
Shares Outstanding
110 Million
Avg Volume
10,491
Avg Price (50 Days)
38.31
Avg Price (200 Days)
21.29
PE Ratio
-92.26
EPS
-0.73
Earnings Announcement
24-Jul-2024
Previous Close
67.57
Open
67.26
Day's Range
66.64 - 68.41
Year Range
8.79 - 99.295
Trading Volume
3,058
1 Day Change
0.09%
5 Day Change
-8.57%
1 Month Change
7.95%
3 Month Change
97.23%
6 Month Change
487.07%
Ytd Change
264.98%
1 Year Change
182.85%
3 Year Change
1182.09%
5 Year Change
742.19%
10 Year Change
358.20%
Max Change
358.20%
No result.
Sector: Healthcare - Healthcare
Industry: Pharmaceuticals, Biotechnology & Life Sciences
Description:
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.